In new drug development, demonstrating a clinically important effect of the new drug is a key element of efficacy evaluations instead of simply showing a statistical significance. However, approaches to demonstrate clinically important effects are unclear and not well recognized among many investigators and sponsors. The minimal clinically important change from baseline (MCIC) and minimal clinically important difference between groups (MCID) are used to assess the clinically important effect.
We state the roles of MCIC and MCID in each phase of new drug development and common approaches to establishing MCIC and MCID. Furthermore, we provide some common approaches on how to practically compare the clinical trial results with the MCIC and MCID and interpret the clinical importance from applications in new drug development. We also suggest incorporating the clinical importance at the planning phase of trials.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Shih WJ. Sample size re-estimation journey for a decade. Stat Med. 2001;20:515–518.
Hung HMJ, Wang SJ, O’Neill RT. Methodological issues with adaptation of clinical trial design. Pharm Stat. 2006;5:99–107.
D’Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues the encounters of academic consultants in statistics. Stat Med. 2003;22:169–186.
Jacobson NS, Truax P. Clinical signifcance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–19.
Cartwright ME, Cohen S, Fleishaker JC, et al. Proof of concept: a PhRMA position paper with recommendations for best practice. Clin Pharmacol Ther. 2010;87(3):278–285.
Chow SC, Liu J P. Design and Analysis of Clinical Trials: Concepts and Methodologies, 2nd ed. New York: Wiley; 2004:438–439.
Golub HL. The need for more effcient trial designs. Stat Med. 2006;25:3231–3235.
Jennison C, Turnbull BW. Effcient group sequential designs when there are several effect sizes under consideration. Stat Med. 2006;25: 917–932.
Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Rahway, NJ: Erlbaum; 1988.
Make B. How can we assess outcomes of clinical trials: the MCID approach. J Chron Obstruct Pulm-on Dis. 2007;4:191–194.
Sierevelt IN, Oldenrijk J, Poolman RW. Is statistical significance clinically important? A guide to judge the clinical relevance of study fndings. J Long-Term Effects Med Implants. 2007;17(2):173–179.
Farrar JT, Young J P, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;149–158.
Burback D, Molnar FJ, John PS, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10:534–540.
Man-Son-Hing M, Laupacis A, O’Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med. 2002;17:469–476.
All authors have disclosed that they are employees of Pfizer Japan Inc.
About this article
Cite this article
Togo, K., Matsuoka, N., Hashigaki, S. et al. Clinically Important Effects in New Drug Development. Ther Innov Regul Sci 45, 805–810 (2011) doi:10.1177/009286151104500517
- Clinically important effect
- Minimum clinically
- important change
- clinically important
- Drug effect